Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ravulizumab in Pediatric Primary IgA Nephropathy (Japan)
jRCT2051250175Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in IgA nephropathy (IgAN) and IgA vasculitis nephritis, sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from Baseline in proteinuria based on UPCR at Week 34. Started Dec 2025; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on jRCT2051250175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250175.